Pharsight

Myrbetriq generic

Myrbetriq is an overactive bladder and neurogenic detrusor overactivity treatment medicine owned by Apgdi. It has an active ingredient called mirabegron. Apgdi obtained the first market authorization for Myrbetriq on June 28, 2012.

When will Myrbetriq generic be available?

The generic version of Myrbetriq is expected to be available only after March 28, 2030. This is the date when the last drug patent of Myrbetriq, with 'Pharmaceutical composition for modified release' as a title, expires. This revised release date for the Myrbetriq generic includes the provision of 'Pediatric Extension', which can prolong the exclusivity period of a patent.

Myrbetriq uses

Myrbetriq comes in an extended-release oral tablet form. Its active ingredient, mirabegron, targets and counteracts the symptoms of overactive bladder and neurogenic detrusor overactivity, such as urge urinary incontinence, urgency, and urinary frequency. It can be used alone or with solifenacin succinate, a muscarinic antagonist. The drug is also approved for pediatric patients aged 3 or more and weighing 35 kg or more with neurogenic detrusor overactivity.

Myrbetriq patent expiration

Myrbetriq, owned by Apgdi, has been protected by a total of 16 patents, with 6 already expired. The last remaining patent, titled 'Pharmaceutical composition for modified release', will expire on March 28, 2030. The generic version of Myrbetriq can only be expected post this patent expiry. Below is the detail of the patents:

EPO Oppostions filed on Myrbetriq

Litigations filed on Myrbetriq

Myrbetriq dosage

Want to ask something?